Andrographolide Suppress Tumor Growth by Inhibiting TLR4/NF-κB Signaling Activation in Insulinoma
Open Access
- 1 January 2014
- journal article
- retracted article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 10 (4) , 404-414
Abstract
Insulinomas are rare tumors, and approximately 10% of insulinomas are malignant. Accumulating evidence has implicated that we still lack effective therapy to treat the patients who are diagnosed with rare malignant insulinoma. Previous studies have reported that Andrographolide (Andro) could inhibit cell cycle progression, reduce cell invasion and induce cell apoptosis in many common cancer cells. However, the effects of andro are cell type-dependent. So we emplored the β-TC-6 cells and the RIP1-Tag2 transgenic mouse model of endogenously growing insulinoma model to elucidate the possible anti-cancer effect of Andro on insulinoma, an uncommon type of malignant cancers in this study. Our experiments revealed that Andro significantly inhibited tumor growth at both the early-stage and the advanced-stage of insulinoma through targeting the TLR4/NF-κB signaling pathway. This work initially provides the evidence that the TLR4/NF-κB signaling pathway might be vital as a potential therapeutic target, and also indispensable in Andro-mediated anti-cancer effect in insulinoma.Keywords
This publication has 29 references indexed in Scilit:
- Rare Cancers Europe: joining forces to tackle a common problemRare Tumors, 2012
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Population-Based Study of Islet Cell CarcinomaAnnals of Surgical Oncology, 2007
- Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cellsBiochemical Pharmacology, 2006
- Andrographolide Interferes with T Cell Activation and Reduces Experimental Autoimmune Encephalomyelitis in the MouseThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Andrographolide Attenuates Inflammation by Inhibition of NF-κB Activation through Covalent Modification of Reduced Cysteine 62 of p50The Journal of Immunology, 2004
- Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculataJournal of Experimental Therapeutics and Oncology, 2003
- Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti‐inflammatory effectBritish Journal of Pharmacology, 2002
- Tumor Cells Utilize Multiple Pathways to Down‐modulate Apoptosis: Lessons from a Mouse Model of Islet Cell CarcinogenesisAnnals of the New York Academy of Sciences, 1999
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999